Switzerland: The first hepatitis C virus (HCV) self-test has been prequalified by the World Health Organization (WHO), which might significantly aid in increasing access to testing and diagnosis and hastening efforts worldwide to eradicate hepatitis C.
The OraQuick HCV self-test, produced by OraSure Technologies, is an expansion of the OraQuick® HCV Rapid Antibody Test, which was first prequalified for professional usage by the WHO in 2017. With the self-test version, which is meant to be used by laypeople, each person receives a single kit that includes all the items required to complete the self-test.
In 2021, the WHO proposed HCV self-testing (HCVST) as an addition to national HCV testing programs. The suggestion was supported by data showing that it can improve service uptake and accessibility, especially for those who might not otherwise test.
HCVST implementation initiatives at the national level, which have received a lot of funding from Unitaid, have demonstrated excellent acceptance and feasibility levels in addition to empowering individuals through access to stigma-free self-care services, personal choice, and autonomy.
“Every day 3500 lives are lost to viral hepatitis. Of the 50 million people living with hepatitis C, only 36% had been diagnosed, and 20% have received curative treatment by the end of 2022,” said Dr. Meg Doherty, WHO Director for the Department of Global HIV, Hepatitis and STI Programmes.
“The addition of this product to the WHO prequalification list provides a safe and effective way to expand HCV testing and treatment services, ensuring more people receive the diagnoses and treatment they need, and ultimately contributing to the global goal of HCV elimination,” Dr. Doherty added.
WHO will keep assessing more HCV self-tests, encourage the application of evidence-based practices, and collaborate with communities to increase the range of alternatives available to all nations.
MOST READ | WHO reports global overuse of antibiotics during COVID-19
